Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 5638.14 | 226 / 226 | 100% | 88.32 | 406 / 406 |
thymus | 100% | 5899.26 | 653 / 653 | 100% | 62.88 | 603 / 605 |
intestine | 100% | 5369.45 | 966 / 966 | 99% | 57.26 | 521 / 527 |
kidney | 100% | 5869.73 | 89 / 89 | 99% | 50.21 | 890 / 901 |
uterus | 100% | 5282.32 | 170 / 170 | 99% | 61.66 | 453 / 459 |
lung | 100% | 6598.98 | 578 / 578 | 98% | 49.19 | 1132 / 1155 |
pancreas | 99% | 2331.30 | 324 / 328 | 99% | 60.50 | 176 / 178 |
stomach | 100% | 3356.02 | 359 / 359 | 98% | 46.43 | 279 / 286 |
bladder | 100% | 4136.48 | 21 / 21 | 97% | 63.67 | 490 / 504 |
ovary | 100% | 4890.14 | 180 / 180 | 97% | 38.76 | 418 / 430 |
breast | 100% | 4645.56 | 459 / 459 | 97% | 57.20 | 1084 / 1118 |
esophagus | 100% | 3311.59 | 1445 / 1445 | 96% | 28.66 | 175 / 183 |
skin | 97% | 1767.76 | 1747 / 1809 | 95% | 53.49 | 450 / 472 |
prostate | 100% | 5409.02 | 245 / 245 | 88% | 35.19 | 442 / 502 |
adrenal gland | 100% | 3897.87 | 258 / 258 | 40% | 11.91 | 92 / 230 |
adipose | 100% | 4502.27 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 72.02 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 142.51 | 29 / 29 |
spleen | 100% | 15035.01 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 61.29 | 45 / 45 |
blood vessel | 100% | 3216.12 | 1332 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 5416.96 | 925 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 1900.61 | 851 / 861 | 0% | 0 | 0 / 0 |
brain | 43% | 443.22 | 1139 / 2642 | 46% | 12.56 | 322 / 705 |
muscle | 39% | 421.57 | 317 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051260 | Biological process | protein homooligomerization |
GO_0006954 | Biological process | inflammatory response |
GO_0055085 | Biological process | transmembrane transport |
GO_0045087 | Biological process | innate immune response |
GO_0050829 | Biological process | defense response to Gram-negative bacterium |
GO_0070269 | Biological process | pyroptotic inflammatory response |
GO_0046931 | Biological process | pore complex assembly |
GO_0032731 | Biological process | positive regulation of interleukin-1 beta production |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0042742 | Biological process | defense response to bacterium |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0009306 | Biological process | protein secretion |
GO_0005615 | Cellular component | extracellular space |
GO_0072559 | Cellular component | NLRP3 inflammasome complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0035580 | Cellular component | specific granule lumen |
GO_0016020 | Cellular component | membrane |
GO_0031966 | Cellular component | mitochondrial membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_1904724 | Cellular component | tertiary granule lumen |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0005829 | Cellular component | cytosol |
GO_0005546 | Molecular function | phosphatidylinositol-4,5-bisphosphate binding |
GO_0001786 | Molecular function | phosphatidylserine binding |
GO_0022829 | Molecular function | wide pore channel activity |
GO_0070300 | Molecular function | phosphatidic acid binding |
GO_1901612 | Molecular function | cardiolipin binding |
GO_0005515 | Molecular function | protein binding |
GO_0070273 | Molecular function | phosphatidylinositol-4-phosphate binding |
Gene name | GSDMD |
Protein name | Gasdermin domain containing 1, isoform CRA_d (Gasdermin-D) Gasdermin-D (Gasdermin domain-containing protein 1) [Cleaved into: Gasdermin-D, N-terminal (GSDMD-NT) (hGSDMD-NTD); Gasdermin-D, C-terminal (GSDMD-CT) (hGSDMD-CTD); Gasdermin-D, p13 (Gasdermin-D, 13 kDa) (13 kDa GSDMD); Gasdermin-D, p40] Gasdermin-D |
Synonyms | DFNA5L GSDMDC1 FKSG10 hCG_32063 |
Description | FUNCTION: [Gasdermin-D]: Precursor of a pore-forming protein that plays a key role in host defense against pathogen infection and danger signals . This form constitutes the precursor of the pore-forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-D, N-terminal) binds to membranes and forms pores, triggering pyroptosis . .; FUNCTION: [Gasdermin-D, N-terminal]: Promotes pyroptosis in response to microbial infection and danger signals . Produced by the cleavage of gasdermin-D by inflammatory caspases CASP1, CASP4 or CASP5 in response to canonical, as well as non-canonical (such as cytosolic LPS) inflammasome activators . After cleavage, moves to the plasma membrane where it strongly binds to inner leaflet lipids, including monophosphorylated phosphatidylinositols, such as phosphatidylinositol 4-phosphate, bisphosphorylated phosphatidylinositols, such as phosphatidylinositol (4,5)-bisphosphate, as well as phosphatidylinositol (3,4,5)-bisphosphate, and more weakly to phosphatidic acid and phosphatidylserine . Homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the release of mature interleukin-1 (IL1B and IL18) and triggering pyroptosis . Gasdermin pores also allow the release of mature caspase-7 (CASP7) (By similarity). In some, but not all, cells types, pyroptosis is followed by pyroptotic cell death, which is caused by downstream activation of ninjurins (NINJ1 or NINJ2), which mediate membrane rupture (cytolysis) . Also forms pores in the mitochondrial membrane, resulting in release of mitochondrial DNA (mtDNA) into the cytosol (By similarity). Gasdermin-D, N-terminal released from pyroptotic cells into the extracellular milieu rapidly binds to and kills both Gram-negative and Gram-positive bacteria, without harming neighboring mammalian cells, as it does not disrupt the plasma membrane from the outside due to lipid-binding specificity . Under cell culture conditions, also active against intracellular bacteria, such as Listeria monocytogenes (By similarity). Also active in response to MAP3K7/TAK1 inactivation by Yersinia toxin YopJ, which triggers cleavage by CASP8 and subsequent activation (By similarity). Strongly binds to bacterial and mitochondrial lipids, including cardiolipin . Does not bind to unphosphorylated phosphatidylinositol, phosphatidylethanolamine nor phosphatidylcholine . .; FUNCTION: [Gasdermin-D, p13]: Transcription coactivator produced by the cleavage by CASP3 or CASP7 in the upper small intestine in response to dietary antigens (By similarity). Required to maintain food tolerance in small intestine: translocates to the nucleus and acts as a coactivator for STAT1 to induce the transcription of CIITA and MHC class II molecules, which in turn induce type 1 regulatory T (Tr1) cells in upper small intestine (By similarity). .; FUNCTION: [Gasdermin-D, p40]: Produced by the cleavage by papain allergen . After cleavage, moves to the plasma membrane and homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the specific release of mature interleukin-33 (IL33), promoting type 2 inflammatory immune response . . |
Accessions | ENST00000628703.2 ENST00000529854.1 E9PQR9 ENST00000631751.1 E9PNZ0 ENST00000525721.1 H0YDB0 G3V1A6 P57764 ENST00000631917.1 ENST00000525208.1 ENST00000633391.1 ENST00000533888.1 ENST00000615119.2 ENST00000533063.5 E9PRF1 E9PIB2 ENST00000533348.5 ENST00000632347.1 ENST00000262580.9 ENST00000632705.1 ENST00000534018.5 ENST00000631550.1 E9PQ48 ENST00000526406.5 ENST00000631389.1 |